← Back to headlines
Barclays Raises Eli Lilly Price Target to $1,400 Amid Tirzepatide Momentum
Barclays has increased its price target for Eli Lilly to $1,400, highlighting the strong momentum of its drug Tirzepatide as a key factor.
5 May, 14:44 — 5 May, 14:44
Sources
Showing 1 of 1 sources
